Optiscan CEO, Dr. Camile Farah, recently sat down with renowned financial journalist Alan Kohler from Intelligent Investor to discuss the company's journey and groundbreaking medical imaging technology. In this insightful conversation, Dr. Farah outlined Optiscan’s transformation from an OEM supplier to a private label medical device manufacturer, the development of its miniaturized confocal endomicroscope, and the disruptive potential of real-time cellular imaging in precision surgery.

The interview also highlighted Optiscan’s innovative business model, which integrates hardware sales with a software subscription for global image streaming and AI-assisted diagnostics. With FDA approval for key devices anticipated by 2026 and a solid financial foundation, Optiscan is positioned to lead the next wave of advancements in medical imaging and digital pathology.

Access the full interview here.